Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCI
- 저널
- 대한췌담도학회지23(3) · pp.108 · 2018
- 피인용
- KCI 0
- ISSN
- 1976-3573
저자
- 김도영제1저자Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
- 최영진Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
- 설영미Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
- 김효정교신저자Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital
초록
Background/Aims: This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection. Methods: We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012. Results: Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012). Conclusions: Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.
키워드
식별자
- KCI
- ART002371603



로그인
연구물 목록으로